Matthew Plunkett, EVP, Corporate Development at CTI BIOPHARMA CORP (CTIC), sold 10,000 shares at $1.37 ($14K) on 2015-11-04, disclosed to the SEC on 2015-11-06.
Scheduled sale ($14k) by EVP, Corporate Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.37 | 1,900 | $3K | 18.8% |
| 2 | $1.38 | 3,500 | $5K | 34.9% |
| 3 | $1.38 | 1,800 | $2K | 18.0% |
| 4 | $1.39 | 1,100 | $2K | 11.1% |
| 5 | $1.39 | 200 | $278 | 2.0% |
| 6 | $1.40 | 1,400 |
| $2K |
| 14.2% |
| 7 | $1.40 | 100 | $140 | 1.0% |
| Total | $1.38 avg | 10,000 | $14K | 100% |
| Filing → |
| CTIC | SELL | 2016-01-06 | $15K | — | Filing → |
| CTIC | SELL | 2015-12-04 | $9K | — | Filing → |
| CTIC | SELL | 2015-10-07 | $15K | — | Filing → |